Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HM97662 |
| Synonyms | |
| Therapy Description |
HM97662 inhibits EZH1 and EZH2, potentially resulting in decreased tumor growth (Cancer Res (2021) 81 (13_Supplement):1142). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HM97662 | HM-97662|HM 97662 | EZH1 inhibitor 5 EZH2 inhibitor 20 | HM97662 inhibits EZH1 and EZH2, potentially resulting in decreased tumor growth (Cancer Res (2021) 81 (13_Supplement):1142). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A inact mut | prostate cancer | predicted - sensitive | HM97662 | Preclinical | Actionable | In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of prostate cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240). | detail... |
| ARID1A inact mut | ovarian cancer | predicted - sensitive | HM97662 | Preclinical | Actionable | In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of ovarian cancer harboring an ARID1A loss-of-function mutation (Cancer Res (2024) 84 (6_Supplement): 3240). | detail... |
| ARID1A inact mut | lung small cell carcinoma | predicted - sensitive | HM97662 | Preclinical | Actionable | In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of small cell lung cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240). | detail... |
| ARID1A inact mut | stomach cancer | predicted - sensitive | HM97662 | Preclinical | Actionable | In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of gastric cancer harboring an ARID1A mutation (Cancer Res (2024) 84 (6_Supplement): 3240). | detail... |
| ARID1A inact mut | urinary bladder cancer | predicted - sensitive | HM97662 | Preclinical | Actionable | In a preclinical study, HM97662 treatment inhibited tumor growth in a xenograft model of bladder cancer harboring an ARID1A loss-of-function mutation (Cancer Res (2024) 84 (6_Supplement): 3240). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05598151 | Phase I | HM97662 | Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors | Recruiting | AUS | 1 |